On April 4, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions, which recommended the transfer to standard care for two completed projects. The projects relate to the management of rare diseases and the strengthening of the regional healthcare structures and processes.

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health and Care Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting. The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.

On April 1, 2022, the entity managing the DRG system in Switzerland, SwissDRG, announced that they will be accepting applications for changes in the DRG system from June 6, 2022, until July 17, 2022. The results of the DRG applications made in 2022 will be reflected in the 2024 version of SwissDRG.

In Q1 of 2022, Health Technology Wales (HTW) published one MedTech-related guidance on transcranial magnetic stimulation in depression treatment. A total of eleven Topic Exploration Reports (TERs) were released in Q1. Based on the TERs conclusions, HTW's Assessment Group decided to proceed with developing an Evidence Appraisal Report (EAR) and Guidance on one topic only - radiofrequency renal denervation for the treatment of resistant hypertension.

In March and April 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty-three health apps are now available at the DiGA Directory.

On March 31, 2022, the updated intra-DRG list was published. It includes the modifications of registration conditions for several devices included in the list. No new devices were added to the list.

On April 12, 2022, NHS England and NHS Improvement (NHSE/I) published 2022/23 priorities and operational planning guidance, including elective recovery planning supporting guidance, capital guidance for 2022-25, and revenue finance and contracting guidance. The 2022/23 priorities and operational planning guidance set out NHSE/I priorities for the year ahead and reconfirms the ongoing need to restore services, meet new care demands, and reduce the care backlogs that are a direct consequence of the pandemic.

On April 4, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) announced funding from the G-BA Innovation Fund for 18 innovative healthcare research projects dedicated to medical guidelines.

On April 8, DRG tariffs for 2022 were published in the Official Journal of the French Republic and on the website of the Agency for Technical Hospital Information.

In March 2022, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (endoscopic balloon dilation for subglottic or tracheal stenosis, intramedullary distraction for lower limb lengthening, endoscopic full thickness removal of gastrointestinal stromal tumors of the stomach, percutaneous insertion of a cystic duct stent after cholecystostomy, and liposuction for chronic lipoedema), four new Medical Technologies Guidance (myCOPD, UroShield, Prontosan for wounds, and 3C Patch for diabetic foot ulcers), one new Diagnostic Guidance (terminated assessment of Freelite assays for multiple myeloma), and six new Medtech Innovation Briefings (Genedrive MT-RNR1 ID System, icobrain for multiple sclerosis, Al for analyzing chest X-ray images, and others). Also, three new clinical guidelines were published, and six were updated.

On April 11, 2022, the Swedish Medical Technologies Product (MTP) Council released recommendations on devices for diagnosing atrial fibrillation via self-recording of electrocardiogram evaluated within the Orderly Introduction framework since 2020. MTP Council outlined that Coala Heart Monitor and Zenicor ECG could be used in certain types of patients only, whereas KardiaMobile, CardioMem CM 100 XT, and PhysioMem should be refrained from use.

The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2022. The most significant changes concern the introduction of new additional flat rates for the observation and care of patients who are given certain medications, adjustment of EBM reproductive medicine definitions, and inclusion of several new codes for PET and PET/CT.